GSK plc (GLAXF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 01:22PM EDT
| Previous Close | 20.20 |
| Open | 19.87 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 20.20 - 20.20 |
| 52 Week Range | 16.65 - 22.12 |
| Volume | |
| Avg. Volume | 1,316 |
| Market Cap | 82.538B |
| Beta (5Y Monthly) | 0.27 |
| PE Ratio (TTM) | 13.56 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.80 (3.97%) |
| Ex-Dividend Date | Feb 22, 2024 |
| 1y Target Est | N/A |
- Business Wire
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
PHILADELPHIA, March 16, 2024--RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
- Business Wire
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
PHILADELPHIA, March 07, 2024--GSK doubles COiMMUNITY grant funding, launches patient resources, as adult vaccination rates begin to show promising rise
- CNW Group
GSK's RSV vaccine, Arexvy, accepted for review by Health Canada for prevention of RSV disease in adults aged 50-59 at increased risk
GSK (GlaxoSmithKline Inc.) has submitted a Supplementary New Drug Submission (SNDS) to Health Canada to expand the use of Arexvy, GSK's respiratory syncytial virus (RSV) vaccine (recombinant, AS01E adjuvanted), to include adults aged 50-59 at increased risk for RSV disease. If approved, GSK's RSV vaccine would be the first vaccine available in Canada to help protect this population.
© 2024 Yahoo. All rights reserved.